Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.81 |
| ▸ | BACE1 | P56817 | 3/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.74 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.74 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.74 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.74 |
| ▸ | STAT3 | P40763 | 2/20 | 0.74 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.74 |
| ▸ | RELA | Q04206 | 2/20 | 0.74 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.74 |
| ▸ | GLO1 | Q04760 | 3/20 | 0.71 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.69 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.69 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.68 |
| ▸ | CA12 | O43570 | 2/20 | 0.68 |
| ▸ | CA1 | P00915 | 2/20 | 0.68 |
| ▸ | CA2 | P00918 | 2/20 | 0.68 |
| ▸ | CA3 | P07451 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16888009 | 1.00 | GSK3B (0.81) | GSK3BBACE1CYP2D6CYP1A2ALOX5 | |
| SCHEMBL3433171 | 0.96 | GSK3B (0.87) | GSK3BBACE1CYP2D6CYP1A2ALOX5 | |
| SCHEMBL29370884 | 0.96 | GSK3B (0.87) | GSK3BBACE1CYP2D6CYP1A2ALOX5 | |
| SCHEMBL6727006 | 0.96 | GSK3B (0.87) | GSK3BBACE1CYP2D6CYP1A2ALOX5 | |
| SCHEMBL3680675 | 0.96 | GSK3B (0.87) | GSK3BBACE1CYP2D6CYP1A2ALOX5 | |
| SCHEMBL242412 | 0.96 | GSK3B (0.87) | GSK3BBACE1CYP2D6CYP1A2ALOX5 | |
| SCHEMBL29855588 | 0.96 | GSK3B (0.87) | GSK3BBACE1CYP2D6CYP1A2ALOX5 | |
| SCHEMBL29332643 | 0.93 | GSK3B (0.79) | GSK3BBACE1CYP2D6CYP1A2ALOX5 | |
| Dimethylcurcumin SCHEMBL3686107 | 0.93 | HDAC1 (0.78) | GSK3BBACE1CYP2D6CYP1A2ALOX5 | |
| Dimethylcurcumin SCHEMBL29354872 | 0.93 | HDAC1 (0.78) | GSK3BBACE1CYP2D6CYP1A2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150025006-A1 | Pharmaceutical Combinations Including Anti-Inflammatory and Antioxidant Conjugates Useful for Treating Metabolic Disorders | GENMEDICA THERAPEUTICS SL (ES) | 2015-01-22 | — | — | US | disclosed |
| US-8575217-B2 | Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders | GENMEDICA THERAPEUTICS SL (ES) | 2013-11-05 | — | — | US | disclosed |
| US-20130281520-A1 | Anti-Inflammatory And Antioxidant Conjugates Useful For Treating Metabolic Disorders | GENMEDICA THERAPEUTICS SL (ES) | 2013-10-24 | — | — | US | disclosed |
| US-8198323-B2 | Curcumin analogues and uses thereof | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2012-06-12 | — | — | US | disclosed |
| US-8198323-B2 | Curcumin analogues and uses thereof | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2012-06-12 | — | — | US | disclosed |
| US-20110224205-A1 | USE OF CURCUMIN OR ITS ANALOGUES IN CANCER THERAPY UTILIZING EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR | NATIONAL TAIWAN UNIVERSITY (TW) | 2011-09-15 | — | — | US | disclosed |
| US-20100197784-A1 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | The University of North Carlina at Chapel Hill (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100197784-A1 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | The University of North Carlina at Chapel Hill (US) | 2010-08-05 | — | — | US | disclosed |
| US-7709535-B2 | Curcumin analogues and uses thereof | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709535-B2 | Curcumin analogues and uses thereof | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-05-04 | — | — | US | disclosed |
| US-20080161391-A1 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161391-A1 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080146660-A1 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2008-06-19 | — | — | US | disclosed |
| US-20080146660-A1 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2008-06-19 | — | — | US | disclosed |
| US-7355081-B2 | androgen receptor antagonists; certain cancers, baldness, hirsutism, behavioral disorders, acne, and inhibition of spermatogenesis if so desired | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2008-04-08 | — | — | US | disclosed |
| US-7355081-B2 | androgen receptor antagonists; certain cancers, baldness, hirsutism, behavioral disorders, acne, and inhibition of spermatogenesis if so desired | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2008-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146660-A1 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | AR, NR5A1, BRDT | GSK3B 2794/4885BACE1 3684/4885CYP2D6 1611/4885 |
| US-20130281520-A1 | Anti-Inflammatory And Antioxidant Conjugates Useful For Treating Metabolic Disorders | HSD17B14, SORD, GPX4 | GSK3B 2207/4885BACE1 4155/4885CYP2D6 6/4885 |
| US-20110224205-A1 | USE OF CURCUMIN OR ITS ANALOGUES IN CANCER THERAPY UTILIZING EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR | EGFR, ERBB2, ERBB4 | GSK3B 1707/4885BACE1 4634/4885CYP2D6 2088/4885 |
| US-20080161391-A1 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | AR, NR5A1, BRDT | GSK3B 2794/4885BACE1 3684/4885CYP2D6 1611/4885 |
| US-20150025006-A1 | Pharmaceutical Combinations Including Anti-Inflammatory and Antioxidant Conjugates Useful for Treating Metabolic Disorders | IAPP, AMY2A, GPR119 | GSK3B 2861/4885BACE1 417/4885CYP2D6 808/4885 |
| US-20100197784-A1 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF | AR, NR5A1, BRDT | GSK3B 2794/4885BACE1 3684/4885CYP2D6 1611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.